Ipilimumab with and without Nivolumab in Patients with Classic Hodgkin Lymphoma with Progression after PD-1 Blockade

被引：0

作者：

Merryman, Reid W. ^{[1
]}

Kline, Justin ^{[2
]}

Redd, Robert A. ^{[3
]}

Welsh, Emma L. ^{[4
]}

Pfaff, Kathleen ^{[4
]}

Lee, Hannah Juhaie ^{[1
]}

Mcdonough, Mikaela M. ^{[5
]}

Ahn, Inhye E. ^{[1
]}

Brown, Jennifer R. ^{[6
]}

Crombie, Jennifer L. ^{[1
]}

Davids, Matthew S. ^{[1
]}

Fisher, David C. ^{[1
]}

Jacobsen, Eric D. ^{[7
]}

Jacobson, Caron A. ^{[1
]}

Kim, Austin I. ^{[1
,5
]}

Odejide, Oreofe O. ^{[1
]}

Parry, Erin M. ^{[1
]}

Ryan, Christine E. ^{[1
]}

Shipp, Margaret A. ^{[1
]}

Armand, Philippe ^{[1
]}

Rodig, Scott J. ^{[4
]}

Abramson, Jeremy S. ^{[8
]}

Lacasce, Ann S. ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA

[2] Univ Chicago Med, Dept Med, Sect Hematol Oncol, Chicago, IL USA

[3] Dana Farber Canc Inst, Dept Data Sci, Boston, MA USA

[4] Brigham & Womens Hosp, Dept Pathol, Boston, MA USA

[5] Dana Farber Canc Inst, Boston, MA USA

[6] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

[7] Dana Farber Canc Inst, Boston, MA USA

[8] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-203414

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1669 / 1670

页数：2

共 50 条

[31] PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma
Nayak, Lakshmi
Iwamoto, Fabio M.
LaCasce, Ann
Mukundan, Srinivasan
Roemer, Margaretha G. M.
Chapuy, Bjoern
Armand, Philippe
Rodig, Scott J.
Shipp, Margaret A.
BLOOD, 2017, 129 (23) : 3071 - 3073
[32] PD-1 Inhibitors Effective in Hodgkin Lymphoma
不详
CANCER DISCOVERY, 2015, 5 (02) : 102 - 103
[33] Pembrolizumab Plus Vorinostat Induces Responses in Patients with Hodgkin Lymphoma Who Are Refractory to Prior PD-1 Blockade
Herrera, Alex F.
Chen, Lu
Budde, L. Elizabeth
Armenian, Saro
Nikolaenko, Liana
Chen, Robert
Daniels, Shari
Kennedy, Neena
Peters, Lacolle
Rosen, Steven T.
Forman, Stephen J.
Popplewell, Leslie L.
Kwak, Larry W.
Mei, Matthew
BLOOD, 2021, 138
[34] OUTCOME OF PD-1 BLOCKADE IN PATIENTS WITH RELAPSED HODGKIN LYMPHOMA AND ACTIVE GRAFT-VERSUS-HOST DISEASE
Minson, A.
Douglas, G.
Grigg, A.
HAEMATOLOGICA, 2017, 102 : 747 - 747
[35] Pembrolizumab Plus Vorinostat Induces Responses in Patients With Hodgkin Lymphoma Who Are Refractory to Prior PD-1 Blockade
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 10 - 11
[36] PD-1/PD-L1 Blockade Accelerates the Progression of Atherosclerosis in Cancer Patients
Dong, Mei
Yu, Ting
Tse, Gary
Lin, Zerun
Lin, Chen
Zhang, Nan
Wang, Rujian
Liu, Tong
Zhong, Lin
CURRENT PROBLEMS IN CARDIOLOGY, 2023, 48 (03) : 1 - 20
[37] Tolerance and Efficacy of Combined Nivolumab and Ipilimumab Following Monotherapy with PD-1 or CTLA-4 Blockade in Metastatic Melanoma
Randhawa, M.
Nguyen, B.
Ali, S.
Yip, D.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 71 - 71
[38] PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacher
Allen, Pamela Blair
Gordon, Leo I.
EXPERT REVIEW OF HEMATOLOGY, 2016, 9 (10) : 939 - 949
[39] Partial Response to Ipilimumab plus Nivolumab after Onset of nephrotic Syndrome under PD-1 Monotherapy
Glutsch, V.
Graen, F.
Weber, J.
Gesierich, A.
Goebeler, M.
Schilling, B.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 36 - 36
[40] Changes in PD-1 and PD-L1 Expression in Cases with Hodgkin Lymphoma after Chemotherapy
Paydas, Semra
Bagir, Emine
Ergin, Melek
Seydaoglu, Gulsah
BLOOD, 2015, 126 (23)

← 1 2 3 4 5 →